nsclc
美 
英
- 網絡非小細胞肺癌(non-small cell lung cancer)；晚期非小細胞肺癌；治療非小細胞肺癌
例句
The clinical manifestations and chest imaging of PSC were similar to that of other types of non small cell lung carcinomas (NSCLC).
結果PSC發病部位以右肺上葉多見，臨床表現及胸部影像學改變與其他類型肺癌相似。
Thoracic radiotherapy has been a key component of local treatment for the patients with non small cell lung cancer(NSCLC).
放療仍是非小細胞肺癌（NSCLC）重要的局部治療手段。
Due to the lack of the valid diagnosis methods of the early-onset lung cancer, unfortunately most patients were diagnosed at late stage.
不幸的是大多數NSCLC患者確診時已進入晚期，其原因是臨床上缺乏用于早期肺癌篩查的方法。
Conclusion: chemotherapy combined with Thymosin on post-operative patients of NSCLC can reduce the side effects of chemotherapy.
結論：在非小細胞肺癌術后患者化療過程中應用胸腺肽可減輕化療毒副反應。
Palliative surgery should be a part of multidisciplinary therapy for selective patients with advanced NSCLC.
在經過選擇的晚期非小細胞肺癌患者，減狀性手術應為綜合治療的一部分。
It indicates that international pharmaceutical companies can take advantages of the resources available to develop more medicines for NSCLC.
說明國際制藥公司充分利用現有資源開發出更多的抗NSCLC藥物。
The methods used to identify disease distribution are the same for NSCLC and SCLC.
此外，確定癌癥的分布的方法同樣適用于肺癌。
None of the htSNP was associated with NSCLC risk in anyone of two case-control studies.
在兩個病例對照組中的任何一個htSNP都與非小細胞肺癌易感性不相關。
A total of 2281 patients with NSCLC were screened for EGFR mutations in their tumors and, of this group, 327 had mutations.
對總共2281名NSCLC患者腫瘤組織進行EGFR變異篩查。在這些患者中，327例患者檢測到變異。
Many studies showed that DNA methylation is specific marker of NSCLC in its diagnosis, staging, treatment and prognosis.
研究顯示，DNA甲基化是非小細胞肺癌（NSCLC）診斷、分期及治療預后特異性較強的標識物。
COX multivariate survival analysis: TNM stage, PTEN and Ezrin expression is an independent prognostic risk factors in NSCLC patients (p05).
COX模型多因素生存分析顯示：TNM分期、PTEN和Ezrin表達是影響NSCLC患者預后的獨立危險因素（p0.05）。
This article summarized the latest developments in chemotherapy and molecular targeted therapy of non-small cell lung cancer.
本文就近年來NSCLC化療及分子靶向治療等方面的研究進展加以綜述。
Objective To evaluate the clinical effect and toxicity of pemetrexed in treating elder advanced non. small cell lung cancer(NSCLC).
目的觀察培美曲塞聯合順鉑治療老年中晚期非小細胞肺癌（NSCLC）的臨床療效和毒性反應。
Objective To investigate the economic effects of three chemotherapy schemes in the treatment of non- small cell lung cancer (NSCLC).
目的探討晚期非小細胞肺癌（NSCLC）不同化療方案的臨床療效和經濟學效果。
What proportion of your NSCLC patients would you conduct this test?
您的NSCLC患者中大概有多少比例的患者會去接受檢測？
The treatment options and associated mortality for NSCLC change dramatically with each stage.
非小細胞肺癌不同的分期其死亡率以及治療方法的選擇也并不相同。
However, little was known about connection between inactivation of the TGFBR1 gene and the presence of CpG methylated promoter in NSCLC.
但是，到目前為止還沒有關于TGFBR1基因失活及其啟動子區CpG位點的甲基化存在情況與非小細胞肺癌的關系的研究報道。
These data demonstrate that H-REV107-1 exerts pro-growth functions within a subset of NSCLC cells in a location-dependent manner.
上述數據顯示，H-REV107-1在部分非小細胞肺癌中發揮促生長作用與其分布有關。
Methods: Ar-He knife was used combined with chemotherapy of allied two medicines containing Pt to treat NSCLC.
方法：選擇直低溫介入冷熱消融治療設備（氬氦刀）聯合含鉑類二藥聯合化療方案進行化療。
The main pathology type is small cell lung cancer(SCLC) and non-small cell lung cancer(NSCLC).
病理類型以小細胞肺癌和非小細胞肺癌為主。
The results were confirmed using two additional adenocarcinoma NSCLC and two nonadenocarcinoma NSCLC cell lines.
用另外兩種NSCLC的腺癌細胞株和兩種NSCLC的非腺癌細胞株也證實了這種結果。
Conclusion CCR7 could induce lymphangiogenesis and promote lymph node metastasis by up regulating the expression of VEGF-D in NSCLC.
結論CCR7可通過上調VEGF-D表達誘導肺癌組織淋巴管形成、促進淋巴結轉移。
Objective To observe the toxicity of shenqifuzheng injection combined with NP regimen in the treatment of non-small cell lung cancer(NSCLC).
目的觀察參芪扶正注射液配合NP方案化療治療非小細胞肺癌（NSCLC）的毒副反應。
Objective To observe the difference of sensitiveness of non-small-cell lung cancer(NSCLC) to neoadjuvant chemotherapy(NACT).
目的研究非小細胞肺癌對新輔助化療敏感度的差異。
The incidence of adverse thrombotic events was higher in the advanced NSCLC group than in the non-advanced NSCLC group.
晚期組血栓性不良事件發生率較非晚期組為高。
Which statements would you choose to further develop your "story" to encompass the usage of Iressa in 2nd line treatment of advanced NSCLC?
為了更好的發展這個“故事”您會選擇哪些描述，且能涵蓋把易瑞沙作為晚期NSCLC患者的二線治療方法？
Methods The clinical data of 18 patients with NSCLC and solitary brain metastasis were retrospectively analysed.
方法回顧性分析18例NSCLC單發腦轉移患者的臨床資料。
In retrospect of advances in target therapy of NSCLC, many problems remained to answer.
回顧肺癌靶向治療的進展，諸多問題需要解決。
Afatinib is under development in several solid tumors including non-small cell lung cancer (NSCLC) and head and neck cancer.
Afatinib被開發用于治療多種實體腫瘤，包括非小細胞肺癌（NSCLC）及頭頸癌。
Objective: To observe the curative effect and adverse event of non-small cell lung cancer(NSCLC) patients who took ZD1839.
目的：對轉移性非小細胞肺癌患者應用ZD1839后的療效及不良事件進行觀察。
Conclusion AD injection in combination with 3D-CRT can enhance the efficacy of elderly patients with NSCLC.
結論艾迪注射液配合3D-CRT可以提高老年非小細胞肺癌患者的治療效果。
Results Heparanase was highly expressed in lung cancer tissues (74. 2%) while negative in epithelia of normal lung tissues.
結果66例NSCLC組織中肝素酶表達陽性率為74.2%，而正常支氣管和肺泡上皮中無陽性表達；
Objective To investigate the significances of telomerase activity and P53 expression in Non-small cell lung cancer (NSCLC).
目的探討非小細胞肺癌（NSCLC）組織中端粒酶活性表達和P53蛋白表達的意義。
Conclusions: CYFRA21-1 is a very valuable marker to diagnose pulmonary carcinoma (especially NSCLC) and to estimate the effect of treatment.
結論：CYFRA21-1是診斷肺癌，特別是非小細胞肺癌，以及觀察療效的一項極有價值的指標。
Past, Present and Future of Targeted Therapy in NSCLC.
非小細胞肺癌靶向治療的過去、現狀和未來。
Based on what you read, how likely would you be to use IRESSA as 1st line treatment in advanced NSCLC in your patients?
根據您剛才讀的內容，您對于晚期NSCLC患者使用易瑞沙作為一線治療的意愿有多大？
Methods 70 cases of NSCLC were randomly divided into two groups (NVB group and VDS group)and treated with NP or MVP regimen.
方法將共收治的晚期NSCLC患者70例隨機分成NVB組和VDS組；分別用NP聯合方案與MVP聯合方案進行對比治療。
We developed a five-gene signature that is closely associated with survival of patients with NSCLC.
我們發現了一個五基因標記與非小細胞肺癌的生存率有密切的關系。
Results The expression of VEGF was significantly higher in NSCLC than that in normal tissue around the cancer (P01).
結果VEGF在癌組織中的表達明顯高于在癌旁正常組織（P0.01）。
AIM: To study the efficiency and toxicities of docetaxel gemcitabine combination on advanced non small cell lung cancer (NSCLC).
前言：目的：研究健擇和多西紫杉醇聯合方案治療晚期非小細胞肺癌（NSCLC）的療效。
